Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University , Boston, Massachusetts 02115, United States.
Bristol-Myers Squibb , Biologics Process and Product Development, 38 Jackson Road, Devens, Massachusetts 01434, United States.
Anal Chem. 2017 May 16;89(10):5294-5302. doi: 10.1021/acs.analchem.6b04892. Epub 2017 Apr 26.
Host cell proteins (HCPs) are process-related impurities of biopharmaceuticals that remain at trace levels despite multiple stages of downstream purification. Currently, there is interest in implementing LC-MS in biopharmaceutical HCP profiling alongside conventional ELISA, because individual species can be identified and quantitated. Conventional data dependent LC-MS is hampered by the low concentration of HCP-derived peptides, which are 5-6 orders of magnitude less abundant than the biopharmaceutical-derived peptides. In this paper, we present a novel data independent acquisition (DIA)-MS workflow to identify HCP peptides using automatically combined targeted and untargeted data processing, followed by verification and quantitation using parallel reaction monitoring (PRM). Untargeted data processing with DIA-Umpire provided a means of identifying HCPs not represented in the assay library used for targeted, peptide-centric, data analysis. An IgG1 monoclonal antibody (mAb) purified by Protein A column elution, cation exchange chromatography, and ultrafiltration was analyzed using the workflow with 1D-LC. Five protein standards added at 0.5 to 100 ppm concentrations were detected in the background of the purified mAb, demonstrating sensitivity to low ppm levels. A calibration curve was constructed on the basis of the summed peak areas of the three highest intensity fragment ions from the highest intensity peptide of each protein standard. Sixteen HCPs were identified and quantitated on the basis of the calibration curve over the range of low ppm to over 100 ppm in the purified mAb sample. The developed approach achieves rapid HCP profiling using 1D-LC and specific identification exploiting the high mass accuracy and resolution of the mass spectrometer.
宿主细胞蛋白(HCP)是生物制药中与工艺相关的杂质,尽管经过多步下游纯化,仍会残留痕量水平的 HCP。目前,人们有兴趣在生物制药 HCP 分析中结合传统的 ELISA 方法同时使用 LC-MS,因为可以对各个物种进行鉴定和定量。传统的数据依赖型 LC-MS 受到 HCP 衍生肽浓度低的限制,其丰度比生物制药衍生肽低 5-6 个数量级。在本文中,我们提出了一种新的无依赖数据采集(DIA)-MS 工作流程,使用自动组合的靶向和非靶向数据处理来鉴定 HCP 肽,然后使用平行反应监测(PRM)进行验证和定量。DIA-Umpire 的非靶向数据处理提供了一种识别在用于靶向、基于肽的数据分析的检测库中未表示的 HCP 的方法。使用 1D-LC 分析经 Protein A 柱洗脱、阳离子交换色谱和超滤纯化的 IgG1 单克隆抗体(mAb)。在纯化 mAb 的背景中检测到以 0.5 至 100ppm 浓度添加的 5 种蛋白标准,表明对低 ppm 水平的灵敏度。基于每个蛋白标准的最高强度肽的三个最高强度片段离子的峰面积总和构建了校准曲线。基于校准曲线,在纯化 mAb 样品中从低 ppm 到超过 100ppm 的范围内鉴定和定量了 16 种 HCP。该方法通过 1D-LC 实现了快速的 HCP 分析,并利用质谱的高质量精度和分辨率进行了特异性鉴定。